The U.S. Food and Drug Administration (FDA) has authorised Lilly’s BAQSIMI (glucagon) nasal powder three mg for the remedy of extreme hypoglycemia in individuals with diabetes ages 4 years and above. BAQSIMI is the primary and solely nasally administered glucagon, and...